The impact of comorbidity on overall survival in elderly nasopharyngeal carcinoma patients: a National Cancer Data Base analysis

被引:24
|
作者
Huang, Ying [1 ,2 ]
Chen, Wei [2 ,3 ]
Haque, Waqar [2 ]
Verma, Vivek [4 ]
Xing, Yan [5 ]
Teh, Bin S. [2 ]
Butler, Edward Brian [2 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Houston Methodist Hosp, Dept Radiat Oncol, 1130 Earle St, Houston, TX 77030 USA
[3] Guangdong Gen Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[4] Allegheny Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA 15212 USA
[5] Houston Methodist Hosp, Dept Hematol & Oncol, Houston, TX 77030 USA
来源
CANCER MEDICINE | 2018年 / 7卷 / 04期
关键词
Comorbidity; elderly; nasopharyngeal carcinoma; National Cancer Data Base (NCDB); prognosis; MAJOR DEPRESSIVE DISORDER; NECK-CANCER; POOR-PROGNOSIS; CO-MORBIDITY; HEAD; RADIOTHERAPY; PREVALENCE; INDEXES; CARE;
D O I
10.1002/cam4.1377
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The number of elderly patients with cancer is increasing. Medical comorbidities are more common in this population. Little is known regarding the prognostic relevance of comorbidities in elderly patients with nasopharyngeal carcinoma (NPC). Using the National Cancer Data Base (NCDB), we queried patients age >65 years diagnosed with NPC and treated with definitive radiation between 2004 and 2012 to examine the association between comorbidity and survival outcomes. Comorbidity was assessed with the Charlson Comorbidity Index (CCI). The influence of comorbidity on overall survival (OS) was evaluated. Cox proportional hazards model was used to study the impact of comorbidity on OS. A total of 1137 patients met the specified criteria. Median follow-up was 61.2 months. Five-year OS was 50.4%. Comorbidities were present in 22.4% of patients, with 17.6% of patients having a CCI score of 1% and 4.8% having a CCI score of >= 2. Patients with a CCI score of 0 had significantly higher 5-year OS than patients with a CCI score of 1 or >= 2 (53.1% vs. 42.2% vs. 32.9%, P < 0.001). In multivariate analysis, CCI was a statistically significant independent prognostic factor for the risk of death of all causes for patients with a CCI score of 1 (hazard ratio [HR]: 1.242; 95% confidence interval [CI]: 1.002-1.539) or CCI score of >= 2 (HR: 1.625; 95% CI: 1.157-2.283) when compared to patients with a CCI score of 0. Comorbidity as measured by CCI is a strong independent prognostic factor for OS in elderly patients with NPC and lends support to the inclusion of comorbidity assessment due to its prognostic value when treating elderly patients with NPC.
引用
收藏
页码:1093 / 1101
页数:9
相关论文
共 50 条
  • [1] Impact of prior cancer on the overall survival of patients with nasopharyngeal carcinoma
    Wang, Xuewen
    Wang, Zhiping
    Chen, Yaying
    Lin, Qin
    Chen, Hong
    Lin, Yihong
    Lu, Linbin
    Zheng, Peichan
    Chen, Xiong
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2022, 43 (01)
  • [2] Inherently poor survival of elderly patients with nasopharyngeal carcinoma
    Zhang, Ye
    Yi, Jun-Lin
    Huang, Xiao-Dong
    Xu, Guo-Zhen
    Xiao, Jian-Ping
    Li, Su-Yan
    Luo, Jing-Wei
    Zhang, Shi-Ping
    Wang, Kai
    Qu, Yuan
    Gao, Li
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (06): : 771 - 776
  • [3] Impact of Comorbidity on Initial Treatment and Overall Survival in Elderly Head and Neck Cancer Patients
    Chokshi, Saurin
    Ghobadi, Armin
    Athar, Mohammed
    Shah, Sachin
    Dowell, Jonathan
    ANTICANCER RESEARCH, 2014, 34 (10) : 5543 - 5546
  • [4] Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer
    Sommat, Kiattisa
    Yit, Nelson Ling Fung
    Wang, Fuqiang
    Lim, John Heng Chi
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (04) : 352 - 358
  • [5] National Practice Patterns for Clinical T1N0 Nasopharyngeal Cancer in the Elderly: A National Cancer Data Base Analysis
    Post, Carl M.
    Lin, Chi
    Adeberg, Sebastian
    Gupta, Mrigank
    Zhen, Weining
    Verma, Vivek
    ANTICANCER RESEARCH, 2018, 38 (03) : 1651 - 1657
  • [6] Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma
    Li, Ying
    Pan, Yuhui
    Huang, Zongwei
    Wu, Lishui
    Wu, Wenxi
    Xu, Siqi
    Chen, Zihan
    Chen, Xin
    Lu, Jun
    Qiu, Sufang
    ONCOLOGIST, 2024, 29 (08) : e1020 - e1030
  • [7] Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma
    Guo, Rui
    Mao, Yan-Ping
    Chen, Lei
    Tang, Ling-Long
    Zhou, Guan-Qun
    Liu, Li-Zhi
    Tian, Li
    Zeng, Mu-Sheng
    Jia, Wei-Hua
    Shao, Jian-Yong
    Lin, Ai-Hua
    Ma, Jun
    ONCOTARGET, 2017, 8 (06) : 10594 - 10601
  • [8] Survival Outcomes With Concurrent Chemoradiation for Elderly Patients With Locally Advanced Head and Neck Cancer According to the National Cancer Data Base
    Amini, Arya
    Jones, Bernard L.
    McDermott, Jessica D.
    Serracino, Hilary S.
    Jimeno, Antonio
    Raben, David
    Ghosh, Debashis
    Bowles, Daniel W.
    Karam, Sana D.
    CANCER, 2016, 122 (10) : 1533 - 1543
  • [9] The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysis
    Wen, Yue-Feng
    Sun, Xue-Song
    Yuan, Li
    Zeng, Li-Si
    Guo, Shan-Shan
    Liu, Li-Ting
    Lin, Chao
    Xie, Hao-Jun
    Liu, Sai-Lan
    Li, Xiao-Yun
    Zhang, Yi-Bin
    Huang, Wen-Jin
    Peng, Hai-Hua
    Liao, Zhi-Wei
    Song, Xian-Lu
    Tang, Qing-Nan
    Liang, Yu-Jing
    Yan, Tin-Jie
    Yang, Jin-Hao
    Yang, Zhen-Chong
    Chen, Qiu-Yan
    Lin, Xiao-Dan
    Tang, Lin-Quan
    Mai, Hai-Qiang
    JOURNAL OF CANCER, 2019, 10 (23): : 5614 - 5621
  • [10] Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis
    Guo, Gang
    Fu, Moushun
    Wei, Shuxiang
    Chen, Ruiwan
    ONCOTARGETS AND THERAPY, 2018, 11 : 1193 - 1201